EXEL

Company Overview — What Does EXELIXIS, INC. Do?

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. EXELIXIS, INC. (EXEL) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael M. Morrissey and employs approximately 1,220 people, headquartered in SOUTH SAN FRANCISCO, California. With a market capitalization of $11.4B, EXEL is one of the prominent companies in the Healthcare sector.

EXELIXIS, INC. (EXEL) Stock Rating — Hold (April 2026)

As of April 2026, EXELIXIS, INC. receives a Hold rating with a composite score of 44.8/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.EXEL ranks #674 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, EXELIXIS, INC. ranks #41 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

EXEL Stock Price and 52-Week Range

EXELIXIS, INC. (EXEL) currently trades at $44.37. The stock lost $1.04 (2.3%) in the most recent trading session. The 52-week high for EXEL is $49.62, which means the stock is currently trading -10.6% from its annual peak. The 52-week low is $32.38, putting the stock 37.0% above its annual trough. Recent trading volume was 978K shares, suggesting relatively thin trading activity.

Is EXEL Overvalued or Undervalued? — Valuation Analysis

EXELIXIS, INC. (EXEL) carries a value factor score of 48/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 16.38x, compared to the Healthcare sector average of 23.63x — a discount of 31%. The price-to-book ratio stands at 5.29x, versus the sector average of 2.75x. The price-to-sales ratio is 5.02x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, EXEL trades at 13.75x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 11.22x.

Overall, EXEL's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

EXELIXIS, INC. Profitability — ROE, Margins, and Quality Score

EXELIXIS, INC. (EXEL) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 32.3%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 24.7% versus the sector average of -33.1%.

On a margin basis, EXELIXIS, INC. reports gross margins of 96.6%, compared to 71.5% for the sector. The operating margin is 36.1% (sector: -66.1%). Net profit margin stands at 30.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 10.8% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

EXEL Debt, Balance Sheet, and Financial Health

EXELIXIS, INC. has a debt-to-equity ratio of 31.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.75x, indicating strong short-term liquidity. Total debt on the balance sheet is $0.

EXEL has a beta of 0.78, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for EXELIXIS, INC. is 69/100, reflecting average volatility within the normal range for its sector.

EXELIXIS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, EXELIXIS, INC. reported revenue of $2.28B and earnings per share (EPS) of $0.72. Net income for the quarter was $698M. Gross margin was 96.6%. Operating income came in at $824M.

In Q3 2026, EXELIXIS, INC. reported revenue of $598M and earnings per share (EPS) of $0.72. Net income for the quarter was $194M. Gross margin was 96.9%. Revenue grew 10.8% year-over-year compared to Q3 2025. Operating income came in at $237M.

In Q2 2026, EXELIXIS, INC. reported revenue of $568M and earnings per share (EPS) of $0.68. Net income for the quarter was $185M. Gross margin was 96.6%. Operating income came in at $214M.

In Q1 2026, EXELIXIS, INC. reported revenue of $555M and earnings per share (EPS) of $0.57. Net income for the quarter was $160M. Gross margin was 96.5%. Revenue grew 0.0% year-over-year compared to Q1 2025. Operating income came in at $187M.

Over the past 8 quarters, EXELIXIS, INC. has demonstrated a growth trajectory, with revenue expanding from $540M to $2.28B. Investors analyzing EXEL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

EXEL Dividend Yield and Income Analysis

EXELIXIS, INC. (EXEL) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

EXEL Momentum and Technical Analysis Profile

EXELIXIS, INC. (EXEL) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 6/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

EXEL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, EXELIXIS, INC. (EXEL) ranks #41 out of 838 stocks based on the Blank Capital composite score. This places EXEL in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing EXEL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full EXEL vs S&P 500 (SPY) comparison to assess how EXELIXIS, INC. stacks up against the broader market across all factor dimensions.

EXEL Next Earnings Date

No upcoming earnings date has been announced for EXELIXIS, INC. (EXEL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy EXEL? — Investment Thesis Summary

EXELIXIS, INC. presents a balanced picture with arguments on both sides. Low volatility (stability score 69/100) reduces downside risk.

In summary, EXELIXIS, INC. (EXEL) earns a Hold rating with a composite score of 44.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on EXEL stock.

Related Resources for EXEL Investors

Explore more research and tools: EXEL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare EXEL head-to-head with peers: EXEL vs AZN, EXEL vs SLGL, EXEL vs VMD.